MAP2K7 and lung carcinoma: Furthermore, a kinase inhibitor screen revealed that PPP2R4-depletion induced resistance against selumetinib (a MEK inhibitor), further confirming the potential of anti-PP2A therapy in MEK inhibitor-resistant lung cancer.